GlobeNewsWire
19 Oct 2026, 06:00 UTC · 3h ago
Impact · against what's priced in
Oculis enters the final stage of its PREDICT-1 trial with a favorable patient mix, increasing the probability of a positive readout. This creates a clear catalyst timeline for licaminlimab, though the ultimate impact depends on the upcoming primary endpoint data.
Scored by the NIS engine · methodology.
What the story claims
2 claims · scored −1 bearish … +1 bullish · 2 new · 0 priced in
Oculis has completed randomization in the PREDICT-1 registrational trial of licaminlimab for TNFR1-mediated dry eye disease.
Newpublished 2026-10-19
So whatCompletion of randomization triggers the countdown to primary endpoint data readout, typically occurring within 6-12 months.
More positive than 81% of claims this week
Two-thirds of the 176 enrolled patients carry the TNFR1 genetic variant linked to enhanced clinical response.
Continue reading
5 related stories
Top 1 mover · tap to explore
Newpublished 2026-10-19
So whatEnriching 117 patients with the high-responder variant increases the statistical probability of meeting the trial's primary endpoint.
More positive than 69% of claims this week
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
11h ago
